About Event
5th Fc-Mediated Function Summit- What’s It About?
The landscape of Fc-Mediated therapies is expanding with transformative innovations for treatments in oncology and autoimmune disease. Building upon the latest scientific breakthroughs and evolving understanding of Fc biology, the summit will dissect the future of antibody research, development, and clinical application.
Navigate the latest insights into Fc receptor interactions and unlock the potential of precisely engineered antibodies for targeted efficacy and enhanced safety profiles
Confront the challenges in therapeutic antibody development head-on by exploring novel Fc engineering strategies and optimizing treatment outcomes across diverse disease indications
Hear from 22+ industry luminaries and thought leaders, including Sally Ward and Richard Blumberg, and a multitude of companies who are pushing the boundaries of antibody engineering and Fc-mediated therapeutics, including Argenx, UCB, and Boehringer Ingelheim
This is your opportunity to be at the forefront of Fc-Mediated treatments in this critical endeavor as the therapeutic potential of antibodies expands and accelerate the development of life-changing treatments for cancer, autoimmune diseases, and beyond.
Enhancing Preclinical Translatability to Advance More Drugs to Clinic: Gain critical insights into designing preclinical studies that accurately predict clinical safety and efficacy for Fc-based therapeutics, alongside understanding the latest regulatory guidelines for seamless translation.
Optimising Antibody Design to Refine Fc Functionality & Extend Half-Life: Explore cutting-edge strategies in antibody design to precisely engineer Fc regions for enhanced target engagement and desired effector functions, while also leveraging Fc mechanisms to significantly extend antibody half-life for improved pharmacokinetics.
Engineering the Fc-Region to Tailor Properties for Specific Applications: Delve into advanced techniques for engineering the Fc region to precisely tailor its properties, including modulated Fc receptor interactions, enhanced stability, and customized effector functions for optimal therapeutic outcomes in diverse disease contexts.
Evaluating Immunogenicity and Safety Risks of Fc-Engineered Therapeutics: Discuss the critical factors influencing immunogenicity and safety profiles of Fc-based molecules as well as the latest strategies for early risk assessment and mitigation to ensure the development of well-tolerated therapies.
Forging Powerful Partnerships to Accelerate Innovation in Safe and Effective Fc-Mediated Therapeutics: Connect with 50+ leading experts from academia, biotech, and pharma to foster collaboration and knowledge sharing, driving the rapid and responsible translation of innovative Fc engineering concepts into transformative treatments for patients.
Who Will You Meet?
The 5th Fc-Mediated Function Summit is the definitive meeting for 50+ senior leaders across biopharma and academia, including pioneering scientists in immunology, oncology, autoimmunity, and drug discovery. This is your exclusive opportunity to gain unparalleled insights from over 18+ renowned speakers and connect with key decision-makers from leading companies in Fc-Mediated therapeutics such Genentech, Argenx, and AbbVie, shaping the future of innovative antibody therapeutics.
What Your Peers Have to Say:
“The talks were all excellent and relevant to the conference topic, enabling a good up-to-date overview of current technology and insights.
Really enjoyed the networking session on the first day - an excellent way to get people talking!”
Senior Director, Translational Science, UCB
“Focused niche and very relevant to our company. The speakers and delegates were super engaged and cued in.”
Director, Research, SeromYx Systems